Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2011

01-05-2011 | Original Paper

A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort

Authors: Tian Yang, Jin Zhang, Jun-Hua Lu, Li-Qun Yang, Guang-Shun Yang, Meng-Chao Wu, Wei-Feng Yu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2011

Login to get access

Abstract

Purpose

Surgical resection remains the gold standard for hepatocellular carcinoma (HCC). Although various staging systems have been developed in recent years, the best tool for staging of HCC remains controversial. The aims of this study were to establish a new staging for patients with HCC undergoing surgical resection and to indentify whether this staging is superior to other staging systems in predicting survival of resectable HCC.

Methods

The subjects of this retrospective study were 958 consecutive HCC patients who underwent surgical resection between 2000 and 2006. Predictors of survival were identified using the Kaplan–Meier method and the Cox model. The disease state was staged by our proposed Eastern staging system by integrating independent risk predictors, as well as six existing staging systems. The accuracy of prediction of 1-, 3-, and 5-year mortality for each system was evaluated by the area under the receiver operating characteristic curve (AUC).

Results

Macroscopic vascular invasion, multiple tumors, performance status 1–2, microscopic vascular invasion, extrahepatic spread, tumor size > 5 cm, albumin < 35 g/L, aspartate aminotransferase > 40 U/L, total bilirubin > 17 μmol/L, and presence of cirrhosis were identified as independent risk factors of survival after resection by multivariate analysis. The comparison of the results of the different staging systems showed that our Eastern staging had the best homogeneity (likelihood ratio χ2 test 543.51, P < 0.001), monotonicity of gradients (linear trend χ2 test 414.97, P < 0.001), and discriminatory ability (the highest AUCs for 1-, 3-, and 5-year mortality).

Conclusions

Compared with other existing staging systems, our proposed Eastern staging system shows a superior predictive ability in a Chinese cohort of patients with resectable HCC, and it can give important prognostic information after surgery.
Literature
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
go back to reference Chen MF, Tsai HP, Jeng LB, Lee WC, Yeh CN, Yu MC, Hung CM (2003) Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg 27:443–447PubMedCrossRef Chen MF, Tsai HP, Jeng LB, Lee WC, Yeh CN, Yu MC, Hung CM (2003) Prognostic factors after resection for hepatocellular carcinoma in noncirrhotic livers: univariate and multivariate analysis. World J Surg 27:443–447PubMedCrossRef
go back to reference Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, Hsieh CB (2007) Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol 33:480–487PubMedCrossRef Chen TW, Chu CM, Yu JC, Chen CJ, Chan DC, Liu YC, Hsieh CB (2007) Comparison of clinical staging systems in predicting survival of hepatocellular carcinoma patients receiving major or minor hepatectomy. Eur J Surg Oncol 33:480–487PubMedCrossRef
go back to reference Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC (2009) Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method–analysis of 2010 Taiwanese patients. Eur J Cancer 45:1630–1639PubMedCrossRef Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC (2009) Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method–analysis of 2010 Taiwanese patients. Eur J Cancer 45:1630–1639PubMedCrossRef
go back to reference Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D’Amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D’Amico DF (2004) The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available. J Hepatol 40:124–131PubMedCrossRef Cillo U, Bassanello M, Vitale A, Grigoletto FA, Burra P, Fagiuoli S, D’Amico F, Ciarleglio FA, Boccagni P, Brolese A, Zanus G, D’Amico DF (2004) The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available. J Hepatol 40:124–131PubMedCrossRef
go back to reference Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D’Amico F, Ciarleglio FA, Bridda A, D’Amico DF (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44:723–731PubMedCrossRef Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D’Amico F, Ciarleglio FA, Bridda A, D’Amico DF (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44:723–731PubMedCrossRef
go back to reference Feinstein AR (1972) Clinical biostatistics. XVI. The process of prognostic stratification. 2. Clin Pharmacol Ther 13:609–624PubMed Feinstein AR (1972) Clinical biostatistics. XVI. The process of prognostic stratification. 2. Clin Pharmacol Ther 13:609–624PubMed
go back to reference Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del GM, Vetrone G, Cavallari A (2003) Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 17(Suppl 2):119–129PubMedCrossRef Grazi GL, Cescon M, Ravaioli M, Ercolani G, Gardini A, Del GM, Vetrone G, Cavallari A (2003) Liver resection for hepatocellular carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long-term survival and tumour recurrence in a single centre. Aliment Pharmacol Ther 17(Suppl 2):119–129PubMedCrossRef
go back to reference Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC Cancer staging manual, 6th edn. Springer, New YorkCrossRef Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (2002) AJCC Cancer staging manual, 6th edn. Springer, New YorkCrossRef
go back to reference Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29–36PubMed
go back to reference Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839–843PubMed
go back to reference Hosmer DW, Hosmer T, Le CS, Lemeshow S (1997) A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16:965–980PubMedCrossRef Hosmer DW, Hosmer T, Le CS, Lemeshow S (1997) A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 16:965–980PubMedCrossRef
go back to reference Investigators TC (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751–755 Investigators TC (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28:751–755
go back to reference Investigators TC (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31:840–845CrossRef Investigators TC (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31:840–845CrossRef
go back to reference Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38:207–215PubMedCrossRef
go back to reference Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW (2006) Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 203:426–435PubMedCrossRef Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW (2006) Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 203:426–435PubMedCrossRef
go back to reference Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94:1760–1769PubMedCrossRef Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94:1760–1769PubMedCrossRef
go back to reference Levy I, Sherman M (2002) Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50:881–885PubMedCrossRef Levy I, Sherman M (2002) Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 50:881–885PubMedCrossRef
go back to reference Llovet JM, Bru C, Bruix J (1999a) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMedCrossRef Llovet JM, Bru C, Bruix J (1999a) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMedCrossRef
go back to reference Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, Bru C, Rodes J, Bruix J (1999b) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67PubMedCrossRef Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, Bru C, Rodes J, Bruix J (1999b) Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29:62–67PubMedCrossRef
go back to reference Llovet JM, Di BAM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef Llovet JM, Di BAM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711PubMedCrossRef
go back to reference Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRef Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRef
go back to reference Luo KZ, Itamoto T, Amano H, Oshita A, Ushitora Y, Tanimoto Y, Ohdan H, Tashiro H, Asahara T (2008) Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol 43:369–377PubMedCrossRef Luo KZ, Itamoto T, Amano H, Oshita A, Ushitora Y, Tanimoto Y, Ohdan H, Tashiro H, Asahara T (2008) Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma. J Gastroenterol 43:369–377PubMedCrossRef
go back to reference Markovic S, Gadzijev E, Stabuc B, Croce LS, Masutti F, Surlan M, Berden P, Brencic E, Visnar-Perovic A, Sasso F, Ferlan-Marolt V, Mucelli FP, Cesar R, Sponza M, Tiribelli C (1998) Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 29:650–659PubMedCrossRef Markovic S, Gadzijev E, Stabuc B, Croce LS, Masutti F, Surlan M, Berden P, Brencic E, Visnar-Perovic A, Sasso F, Ferlan-Marolt V, Mucelli FP, Cesar R, Sponza M, Tiribelli C (1998) Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 29:650–659PubMedCrossRef
go back to reference Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707–716PubMedCrossRef Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41:707–716PubMedCrossRef
go back to reference Noda T, Sasaki Y, Yamada T, Eguchi H, Yano M, Ohigashi H, Ishikawa O, Imaoka S (2009) Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma. J Hepatobiliary Pancreat Surg Noda T, Sasaki Y, Yamada T, Eguchi H, Yano M, Ohigashi H, Ishikawa O, Imaoka S (2009) Usefulness of the CLIP scoring system for prediction of postoperative prognosis of patients with large hepatocellular carcinoma. J Hepatobiliary Pancreat Surg
go back to reference Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928PubMedCrossRef
go back to reference Poon RT, Fan ST (2003) Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 12:35–50 viiiPubMedCrossRef Poon RT, Fan ST (2003) Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. Surg Oncol Clin N Am 12:35–50 viiiPubMedCrossRef
go back to reference Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J (2000a) Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 18:1094–1101PubMed Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J (2000a) Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol 18:1094–1101PubMed
go back to reference Poon RT, Fan ST, Ng IO, Wong J (2000b) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231:544–551PubMedCrossRef Poon RT, Fan ST, Ng IO, Wong J (2000b) Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 231:544–551PubMedCrossRef
go back to reference Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111–1118PubMedCrossRef Poon D, Anderson BO, Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH (2009) Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 10:1111–1118PubMedCrossRef
go back to reference Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, Endo O, Yoshitsugu M, Watanabe N, Matsuzaki S (2002) Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 94:1787–1795PubMedCrossRef Tarao K, Rino Y, Ohkawa S, Tamai S, Miyakawa K, Takakura H, Endo O, Yoshitsugu M, Watanabe N, Matsuzaki S (2002) Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 94:1787–1795PubMedCrossRef
go back to reference Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34:529–534PubMedCrossRef Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34:529–534PubMedCrossRef
go back to reference Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2002) Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg 9:469–477PubMedCrossRef Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2002) Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. J Hepatobiliary Pancreat Surg 9:469–477PubMedCrossRef
go back to reference Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536PubMedCrossRef Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM (2002) Simplified staging for hepatocellular carcinoma. J Clin Oncol 20:1527–1536PubMedCrossRef
go back to reference Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R, Ferretti I, Manenti F (2003) Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 21:441–446PubMedCrossRef Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R, Ferretti I, Manenti F (2003) Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 21:441–446PubMedCrossRef
go back to reference Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN (2002) Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 235:722–730 (discussion 730-1)PubMedCrossRef Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN (2002) Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg 235:722–730 (discussion 730-1)PubMedCrossRef
go back to reference Wild CP, Hall AJ (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462:381–393PubMedCrossRef Wild CP, Hall AJ (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462:381–393PubMedCrossRef
go back to reference Wu M (2001) Clinical advances in primary liver cancer in China. Hepatogastroenterology 48:29–32PubMed Wu M (2001) Clinical advances in primary liver cancer in China. Hepatogastroenterology 48:29–32PubMed
Metadata
Title
A new staging system for resectable hepatocellular carcinoma: comparison with six existing staging systems in a large Chinese cohort
Authors
Tian Yang
Jin Zhang
Jun-Hua Lu
Li-Qun Yang
Guang-Shun Yang
Meng-Chao Wu
Wei-Feng Yu
Publication date
01-05-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0935-3

Other articles of this Issue 5/2011

Journal of Cancer Research and Clinical Oncology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.